Mereo BioPharma (MREO) Total Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has reported Total Current Liabilities for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities fell 17.61% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 17.61% YoY) and the FY2025 annual result came in at $4.3 million, down 68.93% from the prior year.
• Total Current Liabilities advanced to $6.2 million in Q1 2026 per MREO's latest filing, from $4.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for MREO reached as high as $44.3 million in Q2 2022 and fell as low as $4.3 million in Q4 2025.
• A 5-year average of $14.7 million and a median of $11.0 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 221.32% — and 2025, when it tumbled 68.93%.
• Year by year, Total Current Liabilities stood at $28.9 million in 2022, then plunged by 67.23% to $9.5 million in 2023, then jumped by 45.98% to $13.8 million in 2024, then sank by 68.93% to $4.3 million in 2025, then soared by 43.58% to $6.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $6.2 million, $4.3 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.